Fmoc-HoArg-OH

We are Fmoc-HoArg-OH CAS:776277-76-0 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name: (2S)-6-(diaminomethylideneamino)-2-(9H-fluoren-9-ylmethoxycarbonylamino)hexanoic acid
CAS.NO: 776277-76-0
Molecular Formula: C22H26N4O4
Molecular Weight: 410.46600

Synonyms:
Fmoc-HomoArg
Fmoc-L-homoarginine
Fmoc-HoArg-OH
Fmoc-HomoArg-OH

Physical and Chemical Properties:
Density: 1.35g/cm3
Boiling point: /
Melting point: /
Flash point:/
Refractive index:1.649

Specification:
Appearance: White powder
Purity:≥98%

Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Keep the container tightly closed, put it in a tight dispenser, and store in a cool, dry place.
Application:pharmaceutical intermediates.

Related News: “CAR T-cell therapy continues to deliver remarkable outcomes for patients with hematologic malignancies, and next-generation approaches are needed to enable broad and timely patient access and reduce the cost and complexity of therapy,” said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics.67633-97-0 “CAR T-cell therapy continues to deliver remarkable outcomes for patients with hematologic malignancies, and next-generation approaches are needed to enable broad and timely patient access and reduce the cost and complexity of therapy,” said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics.N,N-Dimethylanilinium tetrakis(pentafluorophenyl)borate CAS:118612-00-3 According to statistics, in 2017, China’s total production of chemical drugs reached 3.478 million tons, a year-on-year increase of 1.6%. The main business income showed a steady increase, from 328.972 billion yuan in 2012 to 573.475 billion yuan in 2017. The total profit was 48.644 billion yuan, but profit margins remain low (8.48% in 2017).5,6,7,8-tetrahydro-2-naphthol Among them, Zhejiang pharmaceutical companies accounted for 4 of the world’s top ten API manufacturers.Madeleine Roche, Associate Pharmaceutical Analyst at GlobalData, comments: “Within the top 20 global companies that spent the most on R&D in 2018, the top spender – despite having the second smallest annual revenue of the group at $15.28 billion – is Celgene, whose R&D spend was equal to 37% of its annual revenue.